MEA Biosimilars Market Size, by Country (2024–2032)

Free

in USD Million

Rising GCC Healthcare Investments to Drive MEA Biosimilars Market (2024–2032)

Published by MMR Statistics Reserch Team, November 2025

The MEA Biosimilars Market demonstrated steady regional expansion from 2024 to 2032, with the GCC maintaining its position as the largest and fastest-growing market. GCC values were recorded at USD 657.54 million in 2024, are estimated to reach USD 721.97 million in 2025, and are projected to reach USD 1,557.58 million by 2032, supported by strong healthcare investments, procurement reforms, and improved biologics accessibility. South Africa was valued at USD 324.61 million in 2024 and is projected to rise to USD 700.16 million by 2032, driven by expanding treatment programs and rising adoption of cost-efficient therapies. Egypt also showed consistent momentum in 2024 and is projected to reach USD 510.34 million by 2032, while Nigeria and the Rest of MEA reflect gradual but meaningful uptake as awareness and infrastructure evolve. Overall, rising affordability initiatives and chronic disease burden continue to shape long-term MEA biosimilars demand.

OTHER STATISTICS ON TOPIC

Biosimilars

More statistics on Biosimilars

Download

Information

Unit

in USD Million

Region

Middle East & Africa (MEA)

Time Period

2024-2032

Source Name

Maximize Market Research Pvt. Ltd

Source Link

http://www.maximizemarketresearch.com

Publisher Name

Maximize Market Research Pvt. Ltd

Publisher Link

http://www.maximizemarketresearch.com

Related reports

Market Research Reports on Biosimilars

Explore published research tied to this statistic's topic. Open the featured edition or jump into another region without leaving the page.

Open featured report

Subscriptions

Stay ahead of Biosimilars with tailored access

Sample free-tier statistics or unlock premium coverage for this topic with team-friendly usage rights.

Discover

Try free-tier statistics before committing to a plan.

Start for Free

Professional

Unlock premium coverage across this topic with analyst support.

Select Plan

Contact our team

Need a bespoke deep-dive on Biosimilars?

Tell us about your KPIs and coverage priorities. We can tailor a briefing, share methodology notes, or build a custom dataset that complements the reports and statistics you are browsing.

Talk with an analyst